Hudson Leogrande Joins Prenetics Board as Independent Director
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: Newsfilter
- Board Independence Enhanced: Hudson Leogrande's appointment as an independent director on Prenetics' board increases the proportion of independent directors to 75%, which not only enhances the transparency of the company's governance structure but also lays a solid foundation for IM8's future growth.
- Rapid Revenue Growth for IM8: IM8 achieved over $100 million in annual recurring revenue within just 11 months, with projections to reach between $250 million and $300 million by the end of 2026, showcasing an extraordinary growth trajectory in the supplement industry.
- Social Commerce Strategy: Leogrande's addition is set to drive IM8's expansion on TikTok Shop and Meta, leveraging Comfrt's successful model to significantly enhance customer acquisition efficiency, thereby solidifying IM8's market position in health and longevity.
- Brand Collaboration and Influence: The partnership with high-profile figures like David Beckham, combined with Leogrande's market insights, is expected to accelerate IM8's global influence, driving sales growth in over 40 countries and creating a strong competitive advantage in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRE
About PRE
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Major Wall Street Rating Changes Overview
- UBS Upgrade: UBS upgrades Dynatrace from neutral to buy, citing strong core application performance monitoring demand which is expected to drive modest growth, reflecting a healthy demand backdrop in the market.
- Bank of America Upgrade: Bank of America upgrades Kilroy Realty from neutral to buy, raising the price target from $42 to $44, indicating confidence in improving demand dynamics that are likely to enhance the company's competitive position in the REIT sector.
- DA Davidson Initiation: DA Davidson initiates coverage on Lincoln Electric with a buy rating and a $320 price target, emphasizing its potential as an industrial compounder, which suggests future growth opportunities in the sector.
- Goldman Sachs Neutral Reiteration: Goldman Sachs reiterates Tesla as neutral, forecasting that its Q2 2026 delivery numbers will exceed consensus expectations, thereby boosting confidence in the company's future performance.
See More
Prenetics Global Reports Q1 Revenue of $36M and Raises 2026 IM8 Forecast
- Revenue Growth: Prenetics Global reported first-quarter revenue of $36 million, reflecting a 23% sequential increase driven by strong demand for its health supplements brand, with second-quarter revenue expected between $46 million and $48 million, further solidifying its market position.
- IM8 Forecast Upgrade: The company raised its 2026 IM8 revenue forecast from $180 million-$200 million to $190 million-$210 million, indicating confidence in future growth, particularly in the expanding health supplements market.
- Improved Financial Position: Despite reporting a loss of $23.1 million for the quarter, the company ended March debt-free with $56 million in cash, providing ample funding for future investments and product development.
- Executive Appointment: The appointment of supplements industry veteran Brian Rosin as CFO of IM8 aims to leverage his extensive industry experience to drive further growth in the supplements market.
See More
Prenetics Reports Q1 2026: IM8 Revenue Surge Highlights Growth
- IM8 Revenue Growth: In Q1 2026, IM8 revenue reached $33.8 million, representing a 23.1% increase from Q4 2025 and nearly 6x year-over-year growth, indicating strong market demand and brand momentum.
- Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance from $180 million to $200 million to a new range of $190 million to $210 million, reflecting confidence in future performance and market potential.
- New Product Launch Plans: IM8 plans to launch three new products in Q4 2026 across hydration, creatine, and kids' gummies, aiming to expand market share and meet diverse consumer needs.
- Executive Appointment: The appointment of Brian J. Rosin as CFO of IM8, with extensive experience in consumer health, is expected to drive further global growth and strategic execution for the company.
See More
Hudson Leogrande Joins Prenetics Board as Independent Director
- Board Independence Enhanced: Hudson Leogrande's appointment as an independent director on Prenetics' board increases the proportion of independent directors to 75%, which not only enhances the transparency of the company's governance structure but also lays a solid foundation for IM8's future growth.
- Rapid Revenue Growth for IM8: IM8 achieved over $100 million in annual recurring revenue within just 11 months, with projections to reach between $250 million and $300 million by the end of 2026, showcasing an extraordinary growth trajectory in the supplement industry.
- Social Commerce Strategy: Leogrande's addition is set to drive IM8's expansion on TikTok Shop and Meta, leveraging Comfrt's successful model to significantly enhance customer acquisition efficiency, thereby solidifying IM8's market position in health and longevity.
- Brand Collaboration and Influence: The partnership with high-profile figures like David Beckham, combined with Leogrande's market insights, is expected to accelerate IM8's global influence, driving sales growth in over 40 countries and creating a strong competitive advantage in the market.
See More
Prenetics (PRE) Q1 2026 Earnings Call Transcript
See More
Prenetics Q1 Revenue Grows 333.7% but Misses Expectations
- Revenue Performance: Prenetics reported Q1 revenue of $36 million, reflecting a staggering year-over-year growth of 333.7%, yet it fell short of expectations by $1.9 million, indicating volatility in market demand.
- IM8 Revenue Growth: The IM8 segment generated $33.8 million, up 23.1% from $27.4 million in Q4 2025, showcasing the product line's ongoing growth potential, although market competition remains a concern.
- 2026 Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance to between $190 million and $210 million, up from the previous range of $180 million to $200 million, reflecting management's confidence in future performance.
- Financial Health: As of March 31, 2026, Prenetics maintained a strong, debt-free balance sheet with cash and cash equivalents of $56 million and net current assets of $111.7 million, demonstrating financial flexibility for business expansion.
See More
Major Wall Street Rating Changes Overview
- UBS Upgrade: UBS upgrades Dynatrace from neutral to buy, citing strong core application performance monitoring demand which is expected to drive modest growth, reflecting a healthy demand backdrop in the market.
- Bank of America Upgrade: Bank of America upgrades Kilroy Realty from neutral to buy, raising the price target from $42 to $44, indicating confidence in improving demand dynamics that are likely to enhance the company's competitive position in the REIT sector.
- DA Davidson Initiation: DA Davidson initiates coverage on Lincoln Electric with a buy rating and a $320 price target, emphasizing its potential as an industrial compounder, which suggests future growth opportunities in the sector.
- Goldman Sachs Neutral Reiteration: Goldman Sachs reiterates Tesla as neutral, forecasting that its Q2 2026 delivery numbers will exceed consensus expectations, thereby boosting confidence in the company's future performance.
See More
Prenetics Global Reports Q1 Revenue of $36M and Raises 2026 IM8 Forecast
- Revenue Growth: Prenetics Global reported first-quarter revenue of $36 million, reflecting a 23% sequential increase driven by strong demand for its health supplements brand, with second-quarter revenue expected between $46 million and $48 million, further solidifying its market position.
- IM8 Forecast Upgrade: The company raised its 2026 IM8 revenue forecast from $180 million-$200 million to $190 million-$210 million, indicating confidence in future growth, particularly in the expanding health supplements market.
- Improved Financial Position: Despite reporting a loss of $23.1 million for the quarter, the company ended March debt-free with $56 million in cash, providing ample funding for future investments and product development.
- Executive Appointment: The appointment of supplements industry veteran Brian Rosin as CFO of IM8 aims to leverage his extensive industry experience to drive further growth in the supplements market.
See More
Prenetics Reports Q1 2026: IM8 Revenue Surge Highlights Growth
- IM8 Revenue Growth: In Q1 2026, IM8 revenue reached $33.8 million, representing a 23.1% increase from Q4 2025 and nearly 6x year-over-year growth, indicating strong market demand and brand momentum.
- Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance from $180 million to $200 million to a new range of $190 million to $210 million, reflecting confidence in future performance and market potential.
- New Product Launch Plans: IM8 plans to launch three new products in Q4 2026 across hydration, creatine, and kids' gummies, aiming to expand market share and meet diverse consumer needs.
- Executive Appointment: The appointment of Brian J. Rosin as CFO of IM8, with extensive experience in consumer health, is expected to drive further global growth and strategic execution for the company.
See More
Hudson Leogrande Joins Prenetics Board as Independent Director
- Board Independence Enhanced: Hudson Leogrande's appointment as an independent director on Prenetics' board increases the proportion of independent directors to 75%, which not only enhances the transparency of the company's governance structure but also lays a solid foundation for IM8's future growth.
- Rapid Revenue Growth for IM8: IM8 achieved over $100 million in annual recurring revenue within just 11 months, with projections to reach between $250 million and $300 million by the end of 2026, showcasing an extraordinary growth trajectory in the supplement industry.
- Social Commerce Strategy: Leogrande's addition is set to drive IM8's expansion on TikTok Shop and Meta, leveraging Comfrt's successful model to significantly enhance customer acquisition efficiency, thereby solidifying IM8's market position in health and longevity.
- Brand Collaboration and Influence: The partnership with high-profile figures like David Beckham, combined with Leogrande's market insights, is expected to accelerate IM8's global influence, driving sales growth in over 40 countries and creating a strong competitive advantage in the market.
See More
Prenetics (PRE) Q1 2026 Earnings Call Transcript
See More
Prenetics Q1 Revenue Grows 333.7% but Misses Expectations
- Revenue Performance: Prenetics reported Q1 revenue of $36 million, reflecting a staggering year-over-year growth of 333.7%, yet it fell short of expectations by $1.9 million, indicating volatility in market demand.
- IM8 Revenue Growth: The IM8 segment generated $33.8 million, up 23.1% from $27.4 million in Q4 2025, showcasing the product line's ongoing growth potential, although market competition remains a concern.
- 2026 Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance to between $190 million and $210 million, up from the previous range of $180 million to $200 million, reflecting management's confidence in future performance.
- Financial Health: As of March 31, 2026, Prenetics maintained a strong, debt-free balance sheet with cash and cash equivalents of $56 million and net current assets of $111.7 million, demonstrating financial flexibility for business expansion.
See More
